Clinical trial
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
NCT03004183
Study timeline
Study start (actual)2017-07-01Date precision: day
Registry last updated2024-10-15
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Non-small Cell Lung Cancerunresolved
Metastatic Triple-negative Breast Cancerunresolved
Interventions
ADV/HSV-tkBIOLOGICAL
ValacyclovirDRUG · verified · RxNorm: valacyclovir
SBRTRADIATION
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
The Methodist Hospital Research Institutelead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03004183 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.